Publications

2024

Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study.

Thrombosis and haemostasis.124(3):263-273[DOI] 10.1055/a-2098-6639.[PMID] 37224883.

1 citations·PubMed·Publisher's Site

2023

Acute myocardial infarction following 5-fluorouracil treatment.

Journal of geriatric cardiology : JGC.20(7):551-554[DOI] 10.26599/1671-5411.2023.07.008.[PMID] 37576478.

PubMed·Publisher's Site

2023

Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study.

JACC. Cardiovascular interventions.16(1):36-46[DOI] 10.1016/j.jcin.2022.10.034.[PMID] 36317958.

7 citations·PubMed·Publisher's Site

2023

Clinical and Pre-Clinical Pharmacokinetics and Pharmacodynamics of Bentracimab.

Clinical pharmacokinetics.62(5):673-692[DOI] 10.1007/s40262-023-01245-3.[PMID] 37118383.

PubMed·Publisher's Site

2023

Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium.

Circulation.147(25):1933-1944[DOI] 10.1161/CIRCULATIONAHA.123.064473.[PMID] 37335828.

13 citations·PubMed·Publisher's Site

2023

Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications.

Expert review of clinical pharmacology.16(1):27-38[DOI] 10.1080/17512433.2023.2154651.[PMID] 36455906.

2 citations·PubMed·Publisher's Site

2023

Effect of lipid-lowering therapy on platelet reactivity in patients treated with and without antiplatelet therapy.

Minerva cardiology and angiology.():-[DOI] 10.23736/S2724-5683.23.06411-6.[PMID] 37870424.

PubMed·Publisher's Site

2023

Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis.

Thrombosis and haemostasis.123(6):576-584[DOI] 10.1055/a-2043-0346.[PMID] 36841245.

5 citations·PubMed·Publisher's Site

2023

First case of Arcobacter species isolated in pericardial fluid in an HIV and COVID-19 patient with worsening cardiac tamponade.

IDCases.32():e01771-[DOI] 10.1016/j.idcr.2023.e01771.[PMID] 37151209.

2 citations·PubMed·Publisher's Site

2023

Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.18(15):1254-1265[DOI] 10.4244/EIJ-D-22-00719.[PMID] 36602868.

3 citations·PubMed·Publisher's Site

2023

Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes.

Vascular pharmacology.149():107145-[DOI] 10.1016/j.vph.2023.107145.[PMID] 36720377.

1 citations·PubMed·Publisher's Site

2023

Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention.

Trends in cardiovascular medicine.33(3):133-138[DOI] 10.1016/j.tcm.2021.12.007.[PMID] 34936903.

13 citations·PubMed·Publisher's Site

2023

Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) Study.

JACC. Cardiovascular interventions.16(20):2528-2539[DOI] 10.1016/j.jcin.2023.08.009.[PMID] 37609698.

1 citations·PubMed·Publisher's Site

2022

Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.

European heart journal.43(10):959-967[DOI] 10.1093/eurheartj/ehab836.[PMID] 34918066.

62 citations·PubMed·Publisher's Site

2022

Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease.

European heart journal. Cardiovascular pharmacotherapy.8(5):452-461[DOI] 10.1093/ehjcvp/pvab042.[PMID] 34114623.

1 citations·PubMed·Publisher's Site

2022

Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.

Journal of thrombosis and thrombolysis.54(3):461-469[DOI] 10.1007/s11239-022-02696-4.[PMID] 36048358.

2 citations·PubMed·Publisher's Site

2022

P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention.

Nature reviews. Cardiology.19(12):829-844[DOI] 10.1038/s41569-022-00725-6.[PMID] 35697777.

24 citations·PubMed·Publisher's Site

2022

Patterns and Outcomes of Dual Antiplatelet Therapy Discontinuation After Percutaneous Coronary Intervention.

JACC. Cardiovascular interventions.15(8):807-809[DOI] 10.1016/j.jcin.2022.02.048.[PMID] 35450680.

2 citations·PubMed·Publisher's Site

2022

Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease.

Thrombosis and haemostasis.122(8):1341-1351[DOI] 10.1055/a-1730-8725.[PMID] 34983074.

3 citations·PubMed·Publisher's Site

2022

Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study.

Journal of thrombosis and thrombolysis.54(3):373-381[DOI] 10.1007/s11239-022-02687-5.[PMID] 36036856.

5 citations·PubMed·Publisher's Site

2022

Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.

European heart journal. Cardiovascular pharmacotherapy.8(7):728-737[DOI] 10.1093/ehjcvp/pvac022.[PMID] 35353154.

4 citations·PubMed·Publisher's Site

2022

Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention.

Pharmacogenomics.23(13):723-737[DOI] 10.2217/pgs-2022-0057.[PMID] 35938534.

13 citations·PubMed·Publisher's Site

2022

Reply: The Effects of Cangrelor on Platelet Aggregation in STEMI Patients: Methodological or Pharmacological Issues?

JACC. Cardiovascular interventions.15(2):230-231[DOI] 10.1016/j.jcin.2021.12.002.[PMID] 35057998.

PubMed·Publisher's Site

2022

Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.

European heart journal. Cardiovascular pharmacotherapy.8(7):677-686[DOI] 10.1093/ehjcvp/pvab070.[PMID] 34519777.

47 citations·PubMed·Publisher's Site

2021

Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study.

BMJ open diabetes research & care.9(1):-[DOI] 10.1136/bmjdrc-2020-001939.[PMID] 33637605.

12 citations·PubMed·Publisher's Site

2021

Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations.

Expert review of clinical pharmacology.14(8):963-978[DOI] 10.1080/17512433.2021.1927709.[PMID] 33993817.

23 citations·PubMed·Publisher's Site

2021

Genotype-Guided Antiplatelet Therapy in Patients With Coronary Artery Disease.

JACC. Cardiovascular interventions.14(7):751-753[DOI] 10.1016/j.jcin.2021.02.005.[PMID] 33744206.

2 citations·PubMed·Publisher's Site

2021

Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Lancet (London, England).397(10283):1470-1483[DOI] 10.1016/S0140-6736(21)00533-X.[PMID] 33865495.

112 citations·PubMed·Publisher's Site

2021

Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With Cangrelor.

JACC. Cardiovascular interventions.14(21):2410-2412[DOI] 10.1016/j.jcin.2021.07.051.[PMID] 34736741.

3 citations·PubMed·Publisher's Site

2021

Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor.

Journal of thrombosis and thrombolysis.51(3):741-747[DOI] 10.1007/s11239-021-02386-7.[PMID] 33582955.

6 citations·PubMed·Publisher's Site

2020

Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.

Thrombosis and haemostasis.120(1):83-93[DOI] 10.1055/s-0039-1695772.[PMID] 31470444.

19 citations·PubMed·Publisher's Site

2020

Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS-6 Study.

Circulation.142(15):1500-1502[DOI] 10.1161/CIRCULATIONAHA.120.048770.[PMID] 33044856.

10 citations·PubMed·Publisher's Site

2020

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study.

Journal of the American Heart Association.9(8):e015865-[DOI] 10.1161/JAHA.120.015865.[PMID] 32306797.

19 citations·PubMed·Publisher's Site

2020

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing.

JACC. Basic to translational science.5(5):419-428[DOI] 10.1016/j.jacbts.2020.02.009.[PMID] 32478205.

19 citations·PubMed·Publisher's Site

2019

Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine.

JACC. Cardiovascular interventions.12(16):1538-1549[DOI] 10.1016/j.jcin.2019.05.028.[PMID] 31377269.

26 citations·PubMed·Publisher's Site

2019

Endocarditis caused by Stenotrophomonas maltophilia-A rare presentation of an emerging opportunistic pathogen.

IDCases.17():e00556-[DOI] 10.1016/j.idcr.2019.e00556.[PMID] 31193238.

4 citations·PubMed·Publisher's Site

2019

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study.

JACC. Basic to translational science.4(7):763-775[DOI] 10.1016/j.jacbts.2019.07.011.[PMID] 31998847.

14 citations·PubMed·Publisher's Site

2019

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Circulation.139(14):1661-1670[DOI] 10.1161/CIRCULATIONAHA.118.038317.[PMID] 30630341.

95 citations·PubMed·Publisher's Site

2019

Switching Oral Anticoagulant Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.

JACC. Cardiovascular interventions.12(23):2342-2345[DOI] 10.1016/j.jcin.2019.10.017.[PMID] 31806215.

1 citations·PubMed·Publisher's Site

2018

"Malignant" right coronary artery presenting as an ST-segment elevation myocardial infarction-a case report.

Journal of geriatric cardiology : JGC.15(6):467-468[DOI] 10.11909/j.issn.1671-5411.2018.07.001.[PMID] 30108621.

4 citations·PubMed·Publisher's Site

2018

Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention.

Nature reviews. Cardiology.15(8):480-496[DOI] 10.1038/s41569-018-0049-1.[PMID] 29973709.

160 citations·PubMed·Publisher's Site

2018

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.

Journal of translational medicine.16(1):92-[DOI] 10.1186/s12967-018-1469-8.[PMID] 29642909.

37 citations·PubMed·Publisher's Site

2018

Diabetes and antiplatelet therapy: from bench to bedside.

Cardiovascular diagnosis and therapy.8(5):594-609[DOI] 10.21037/cdt.2018.05.09.[PMID] 30498684.

40 citations·PubMed·Publisher's Site

2018

Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy.

Progress in cardiovascular diseases.60(4-5):478-490[DOI] 10.1016/j.pcad.2017.12.004.[PMID] 29291426.

51 citations·PubMed·Publisher's Site

2018

Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.

Clinical pharmacology and therapeutics.104(4):664-674[DOI] 10.1002/cpt.1006.[PMID] 29280137.

81 citations·PubMed·Publisher's Site

2018

Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.

Circulation.137(23):2450-2462[DOI] 10.1161/CIRCULATIONAHA.118.033983.[PMID] 29526833.

43 citations·PubMed·Publisher's Site

2018

Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.

Journal of cardiovascular pharmacology and therapeutics.23(1):23-37[DOI] 10.1177/1074248417708617.[PMID] 28565918.

16 citations·PubMed·Publisher's Site

2018

Role of genetic testing in patients undergoing percutaneous coronary intervention.

Expert review of clinical pharmacology.11(2):151-164[DOI] 10.1080/17512433.2017.1353909.[PMID] 28689434.

53 citations·PubMed·Publisher's Site

2018

Standard- and Low-Dose Ticagrelor After Percutaneous Coronary Intervention: Finding the Balance for Patients With Stable Coronary Artery Disease.

Circulation.138(13):1301-1303[DOI] 10.1161/CIRCULATIONAHA.118.036240.[PMID] 30354428.

1 citations·PubMed·Publisher's Site

2018

Syncope in a middle-aged man.

Emergency medicine journal : EMJ.35(6):395-401[DOI] 10.1136/emermed-2017-207381.[PMID] 29784832.

PubMed·Publisher's Site

2018

The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts.

Expert review of hematology.11(1):5-12[DOI] 10.1080/17474086.2018.1400378.[PMID] 29091481.

17 citations·PubMed·Publisher's Site

2018

The Quest for the Optimal Periprocedural Antithrombotic Treatment Strategy in ACS Patients Undergoing PCI.

Journal of the American College of Cardiology.71(11):1243-1245[DOI] 10.1016/j.jacc.2018.01.040.[PMID] 29544608.

4 citations·PubMed·Publisher's Site

2017

Antithrombotic therapy for patients with STEMI undergoing primary PCI.

Nature reviews. Cardiology.14(6):361-379[DOI] 10.1038/nrcardio.2017.18.[PMID] 28230176.

71 citations·PubMed·Publisher's Site

2017

Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status.

Thrombosis and haemostasis.117(5):940-947[DOI] 10.1160/TH16-09-0703.[PMID] 28300867.

18 citations·PubMed·Publisher's Site

2017

Crushed ticagrelor in comatose patients treated with primary percutaneous coronary intervention.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.12(14):1681-1683[DOI] 10.4244/EIJV12I14A276.[PMID] 28216470.

2 citations·PubMed·Publisher's Site

2017

De-Escalation of Platelet P2Y12 Receptor Inhibiting Therapy After Percutaneous Coronary Intervention: Does One Size Fit All?

JACC. Cardiovascular interventions.10(24):2571-2573[DOI] 10.1016/j.jcin.2017.10.007.[PMID] 29268887.

4 citations·PubMed·Publisher's Site

2017

Drug-Drug Interactions When Switching Between Intravenous and Oral P2Y12 Receptor Inhibitors: How Real Is It?

JACC. Cardiovascular interventions.10(2):130-132[DOI] 10.1016/j.jcin.2016.11.021.[PMID] 28104205.

6 citations·PubMed·Publisher's Site

2017

Impact of chronic kidney disease on platelet P2Y12 receptor signalling in patients with type 2 diabetes mellitus.

Thrombosis and haemostasis.117(1):201-203[DOI] 10.1160/TH16-08-0594.[PMID] 27786340.

6 citations·PubMed·Publisher's Site

2017

Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.

Journal of the American Heart Association.6(4):-[DOI] 10.1161/JAHA.117.005650.[PMID] 28356282.

31 citations·PubMed·Publisher's Site

2017

Institutional profile: University of Florida Health Personalized Medicine Program.

Pharmacogenomics.18(5):421-426[DOI] 10.2217/pgs-2017-0028.[PMID] 28346068.

53 citations·PubMed·Publisher's Site

2017

International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies.

Circulation.136(20):1955-1975[DOI] 10.1161/CIRCULATIONAHA.117.031164.[PMID] 29084738.

242 citations·PubMed·Publisher's Site

2017

In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor-Mediated Signaling in Ticagrelor-Treated Patients.

JACC. Cardiovascular interventions.10(13):1374-1375[DOI] 10.1016/j.jcin.2017.04.027.[PMID] 28683943.

8 citations·PubMed·Publisher's Site

2017

Oral trans-mucosal administration of ticagrelor: is this really the future?

Thrombosis and haemostasis.117(5):826-828[DOI] 10.1160/TH17-03-0177.[PMID] 28331923.

1 citations·PubMed·Publisher's Site

2017

Percutaneous Interventional Repair of an Intraoperative Right Coronary Artery Tear.

JACC. Cardiovascular interventions.10(23):2464-2465[DOI] 10.1016/j.jcin.2017.07.039.[PMID] 29153495.

PubMed·Publisher's Site

2017

Reply: Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.

Journal of the American College of Cardiology.69(2):250-251[DOI] 10.1016/j.jacc.2016.09.982.[PMID] 28081837.

PubMed·Publisher's Site

2017

Switching from ticagrelor to clopidogrel: New answers and further questions.

Thrombosis and haemostasis.117(2):207-208[DOI] 10.1160/TH16-12-0909.[PMID] 28004060.

3 citations·PubMed·Publisher's Site

2017

Switching P2Y12 Receptor Inhibiting Therapies.

Interventional cardiology clinics.6(1):67-89[DOI] 10.1016/j.iccl.2016.08.006.[PMID] 27886824.

7 citations·PubMed·Publisher's Site

2017

The role of oral anticoagulant therapy in patients with acute coronary syndrome.

Therapeutic advances in hematology.8(12):353-366[DOI] 10.1177/2040620717733691.[PMID] 29204262.

15 citations·PubMed·Publisher's Site

2016

A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.

European heart journal.37(35):2722-30[DOI] 10.1093/eurheartj/ehv744.[PMID] 26848148.

48 citations·PubMed·Publisher's Site

2016

A Safety Evaluation of Cangrelor in Patients Undergoing PCI.

Expert opinion on drug safety.15(2):275-85[DOI] 10.1517/14740338.2016.1133585.[PMID] 26680584.

12 citations·PubMed·Publisher's Site

2016

Antithrombotic Therapy for Secondary Prevention in Patients With Diabetes Mellitus and Coronary Artery Disease.

Circulation journal : official journal of the Japanese Circulation Society.80(4):791-801[DOI] 10.1253/circj.CJ-16-0208.[PMID] 26984587.

16 citations·PubMed·Publisher's Site

2016

Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.

Journal of the American College of Cardiology.67(17):1994-2004[DOI] 10.1016/j.jacc.2016.02.045.[PMID] 27012781.

97 citations·PubMed·Publisher's Site

2016

Dual antiplatelet therapy after coronary stenting.

Expert opinion on pharmacotherapy.17(13):1775-87[DOI] 10.1080/14656566.2016.1202924.[PMID] 27309035.

9 citations·PubMed·Publisher's Site

2016

Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.

Thrombosis and haemostasis.115(3):622-31[DOI] 10.1160/TH15-06-0467.[PMID] 26633836.

20 citations·PubMed·Publisher's Site

2016

Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors.

Thrombosis and haemostasis.116(6):1060-1069[DOI] .[PMID] 27488362.

7 citations·PubMed·Publisher's Site

2016

New oral anticoagulants and dual antiplatelet therapy: Focus on apixaban.

International journal of cardiology.225():154-158[DOI] 10.1016/j.ijcard.2016.09.125.[PMID] 27723533.

PubMed·Publisher's Site

2016

Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.

Circulation.134(11):780-92[DOI] 10.1161/CIRCULATIONAHA.116.023402.[PMID] 27559041.

75 citations·PubMed·Publisher's Site

2016

Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.

JACC. Cardiovascular interventions.9(11):1089-98[DOI] 10.1016/j.jcin.2016.02.039.[PMID] 27013060.

32 citations·PubMed·Publisher's Site

2016

Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.

Journal of the American College of Cardiology.67(10):1145-1154[DOI] 10.1016/j.jacc.2015.12.062.[PMID] 26965534.

98 citations·PubMed·Publisher's Site

2016

Switching P2Y12-receptor inhibitors in patients with coronary artery disease.

Nature reviews. Cardiology.13(1):11-27[DOI] 10.1038/nrcardio.2015.113.[PMID] 26283269.

134 citations·PubMed·Publisher's Site

2016

The Conundrum of Platelet P2Y12 Inhibition in ST-Segment Elevation Myocardial Infarction.

Circulation journal : official journal of the Japanese Circulation Society.80(12):2429-2431[DOI] .[PMID] 27795489.

3 citations·PubMed·Publisher's Site

2016

The Paradox of Smoking and Clopidogrel Effect　- Dr Jekyll or Mr Hyde?

Circulation journal : official journal of the Japanese Circulation Society.80(7):1529-31[DOI] 10.1253/circj.CJ-16-0508.[PMID] 27302849.

2 citations·PubMed·Publisher's Site

2016

Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction.

Trends in cardiovascular medicine.26(4):321-34[DOI] 10.1016/j.tcm.2015.08.002.[PMID] 26391344.

3 citations·PubMed·Publisher's Site

2015

[Non-cardiac surgery in patients with previous percutaneous coronary intervention according to the 2014 European guidelines].

Giornale italiano di cardiologia (2006).16(5):277-80[DOI] 10.1714/1870.20424.[PMID] 25994462.

PubMed·Publisher's Site

2015

Acute coronary syndromes: applying practice guidelines and defining the unmet need in clinical practice.

The American journal of cardiology.115(5 Suppl):1A-2A[DOI] 10.1016/j.amjcard.2015.01.001.[PMID] 25728970.

PubMed·Publisher's Site

2015

Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable patients with CAD treated with dual ANtiplatelet therapy) study.

Journal of thrombosis and thrombolysis.40(3):331-9[DOI] 10.1007/s11239-015-1203-9.[PMID] 25761430.

1 citations·PubMed·Publisher's Site

2015

Defining the link between chronic kidney disease, high platelet reactivity, and clinical outcomes in clopidogrel-treated patients undergoing percutaneous coronary intervention.

Circulation. Cardiovascular interventions.8(6):e002760-[DOI] 10.1161/CIRCINTERVENTIONS.115.002760.[PMID] 26056251.

12 citations·PubMed·Publisher's Site

2015

Drug-drug interactions between clopidogrel and novel cardiovascular drugs.

European journal of pharmacology.765():332-6[DOI] 10.1016/j.ejphar.2015.08.059.[PMID] 26341013.

8 citations·PubMed·Publisher's Site

2015

Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.

JACC. Cardiovascular interventions.8(11):1457-1467[DOI] 10.1016/j.jcin.2015.02.030.[PMID] 26404199.

68 citations·PubMed·Publisher's Site

2015

Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike.

Progress in cardiovascular diseases.58(3):267-77[DOI] 10.1016/j.pcad.2015.08.009.[PMID] 26277706.

14 citations·PubMed·Publisher's Site

2015

Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.

JACC. Cardiovascular interventions.8(8):1075-1083[DOI] 10.1016/j.jcin.2015.02.022.[PMID] 26117466.

4 citations·PubMed·Publisher's Site

2015

Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development.

Future cardiology.11(5):547-64[DOI] 10.2217/fca.15.50.[PMID] 26406386.

13 citations·PubMed·Publisher's Site

2015

Reply: elevated serum fibrinogen: an independent link between diabetes mellitus, impaired on-clopidogrel platelet inhibition, and major adverse cardiac events after percutaneous coronary intervention.

Journal of the American College of Cardiology.65(16):1714-1715[DOI] 10.1016/j.jacc.2014.12.069.[PMID] 25908082.

PubMed·Publisher's Site

2015

Role of thromboelastography and rapid thromboelastography to assess the pharmacodynamic effects of vitamin K antagonists.

Journal of thrombosis and thrombolysis.40(1):118-25[DOI] 10.1007/s11239-014-1130-1.[PMID] 25129122.

12 citations·PubMed·Publisher's Site

2014

Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.

Journal of cardiovascular translational research.7(1):53-63[DOI] 10.1007/s12265-013-9535-3.[PMID] 24395495.

21 citations·PubMed·Publisher's Site

2014

Erratum to: Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.

Journal of thrombosis and thrombolysis.37(3):358-[DOI] 10.1007/s11239-013-1003-z.[PMID] 24101257.

PubMed·Publisher's Site

2014

Impact of cigarette smoking on P2Y12 receptor binding activity before and after clopidogrel therapy in patients with coronary artery disease.

Journal of cardiovascular translational research.7(1):47-52[DOI] 10.1007/s12265-013-9530-8.[PMID] 24357254.

6 citations·PubMed·Publisher's Site

2014

Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.

Journal of the American College of Cardiology.64(10):1005-14[DOI] 10.1016/j.jacc.2014.06.1170.[PMID] 25190236.

133 citations·PubMed·Publisher's Site

2014

Perspectives on the management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery.

Current opinion in cardiology.29(6):553-63[DOI] 10.1097/HCO.0000000000000104.[PMID] 25144343.

5 citations·PubMed·Publisher's Site

2014

Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.

JACC. Cardiovascular interventions.7(4):426-34[DOI] 10.1016/j.jcin.2013.11.019.[PMID] 24630878.

27 citations·PubMed·Publisher's Site

2014

Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.

Journal of thrombosis and thrombolysis.37(2):131-8[DOI] 10.1007/s11239-013-0979-8.[PMID] 23943337.

12 citations·PubMed·Publisher's Site

2014

Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.

Thrombosis and haemostasis.111(2):258-65[DOI] 10.1160/TH13-07-0529.[PMID] 24154863.

10 citations·PubMed·Publisher's Site

2014

Platelet function testing in contemporary clinical and interventional practice.

Current treatment options in cardiovascular medicine.16(5):300-[DOI] 10.1007/s11936-014-0300-y.[PMID] 24652579.

33 citations·PubMed·Publisher's Site

2014

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar.

Vascular health and risk management.10():177-88[DOI] 10.2147/VHRM.S36045.[PMID] 24729713.

14 citations·PubMed·Publisher's Site

2013

Cangrelor: a review on pharmacology and clinical trial development.

Expert review of cardiovascular therapy.11(10):1279-91[DOI] 10.1586/14779072.2013.837701.[PMID] 24138516.

50 citations·PubMed·Publisher's Site

2013

Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation.

Journal of thrombosis and thrombolysis.35(2):155-64[DOI] 10.1007/s11239-012-0846-z.[PMID] 23184484.

22 citations·PubMed·Publisher's Site

2013

Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation.

Thrombosis and haemostasis.110(4):777-84[DOI] 10.1160/TH13-05-0400.[PMID] 23884248.

7 citations·PubMed·Publisher's Site

2013

Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy.

JACC. Cardiovascular interventions.6(2):182-4[DOI] 10.1016/j.jcin.2012.10.007.[PMID] 23428011.

10 citations·PubMed·Publisher's Site

2013

Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus.

Journal of thrombosis and thrombolysis.36(1):14-7[DOI] 10.1007/s11239-012-0828-1.[PMID] 23143668.

13 citations·PubMed·Publisher's Site

2013

Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.81(1):42-9[DOI] 10.1002/ccd.24416.[PMID] 22431415.

18 citations·PubMed·Publisher's Site

2013

Platelet function profiles in patients with diabetes mellitus.

Journal of cardiovascular translational research.6(3):329-45[DOI] 10.1007/s12265-013-9449-0.[PMID] 23404189.

40 citations·PubMed·Publisher's Site

2013

Switching from prasugrel to clopidogrel: navigating in unknown waters.

JACC. Cardiovascular interventions.6(2):166-8[DOI] 10.1016/j.jcin.2012.12.001.[PMID] 23428008.

8 citations·PubMed·Publisher's Site

2013

Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice.

Therapeutic advances in cardiovascular disease.7(4):197-213[DOI] 10.1177/1753944713487781.[PMID] 23818658.

44 citations·PubMed·Publisher's Site

2012

[The GRAVITAS study].

Giornale italiano di cardiologia (2006).13(1):1-5[DOI] 10.1714/1015.11050.[PMID] 22322466.

PubMed·Publisher's Site

2012

Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.

Platelets.23(7):537-51[DOI] .[PMID] 22812566.

16 citations·PubMed·Publisher's Site

2012

Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.

Future cardiology.8(4):503-11[DOI] 10.2217/fca.12.35.[PMID] 22871190.

3 citations·PubMed·Publisher's Site

2012

Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus.

Thrombosis and haemostasis.108(5):930-6[DOI] 10.1160/TH12-06-0397.[PMID] 22782352.

12 citations·PubMed·Publisher's Site

2012

Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers.

Journal of thrombosis and thrombolysis.34(3):297-9[DOI] .[PMID] 22923024.

7 citations·PubMed·Publisher's Site

2011

Carotid plaque characterisation by IVUS-VH during carotid stenting: the "eyes wide shut" between plaque morphology and symptoms.

Minerva cardioangiologica.59(6):591-600[DOI] .[PMID] 22134471.

3 citations·PubMed·Publisher's Site

2011

Evaluation of re-endothelization extent at mid-term follow-up after drug eluting balloon plus bare metal stent implantation during primary coronary angioplasty: insight from OCT imaging.

Minerva cardioangiologica.59(1):109-12[DOI] .[PMID] 21285936.

1 citations·PubMed·Publisher's Site

2009

Assessing coronary heart disease in women.

Maturitas.62(3):243-7[DOI] 10.1016/j.maturitas.2008.12.013.[PMID] 19200669.

11 citations·PubMed·Publisher's Site

Show More